Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc (ATNM) Historical Volatility
ATNM's 30 day historical volatility is 126.11%, in the 100th percentile of readings over the past year. This is a high percentile, meaning Actinium Pharmaceuticals Inc shares have swung far more than usual. ATNM's 30 day implied volatility sits at 0.01%, with an IV Rank of 2.98%, leaving IV 126.10 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking ATNM historical volatility helps you see how much Actinium Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ATNM's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ATNM 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ATNM's 30 day historical volatility, or ATNM HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ATNM's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →